BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 25744769)

  • 1. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.
    Xie CM; Wei W; Sun Y
    J Genet Genomics; 2013 Mar; 40(3):97-106. PubMed ID: 23522382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets.
    Wei D; Sun Y
    Genes Cancer; 2010 Jul; 1(7):700-7. PubMed ID: 21103004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3 ubiquitin ligases as cancer targets and biomarkers.
    Sun Y
    Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of F-BOX proteins in progression and development of human malignancies.
    Uddin S; Bhat AA; Krishnankutty R; Mir F; Kulinski M; Mohammad RM
    Semin Cancer Biol; 2016 Feb; 36():18-32. PubMed ID: 26410033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCF E3 ubiquitin ligases as anticancer targets.
    Jia L; Sun Y
    Curr Cancer Drug Targets; 2011 Mar; 11(3):347-56. PubMed ID: 21247385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
    Daks AA; Melino D; Barlev NA
    Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis.
    Lau AW; Fukushima H; Wei W
    Front Biosci (Landmark Ed); 2012 Jun; 17(6):2197-212. PubMed ID: 22652772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.
    Jiang Q; Li F; Cheng Z; Kong Y; Chen C
    Cell Mol Life Sci; 2020 Apr; 77(8):1483-1495. PubMed ID: 31637449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
    Satija YK; Bhardwaj A; Das S
    Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E3 ubiquitin ligases in cancer and implications for therapies.
    Wang D; Ma L; Wang B; Liu J; Wei W
    Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of approaches for screening for ubiquitin ligase inhibitors.
    Sun Y
    Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
    Pray TR; Parlati F; Huang J; Wong BR; Payan DG; Bennett MK; Issakani SD; Molineaux S; Demo SD
    Drug Resist Updat; 2002 Dec; 5(6):249-58. PubMed ID: 12531181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.